Magaldrato Teva (Magaldrate Anhydrous)

Magaldrate neutralises gastric hydrochloric acid through a chemical reaction that produces magnesium chloride, aluminum chloride and water. This reaction raises the pH of stomach contents, decreasing acidity and providing rapid symptom relief in acid‑related gastrointestinal conditions.

The appropriate dose of Magaldrato Teva is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms and clinical response. Patients should follow the prescriber’s instructions and the product label.

Safety data for magaldrate in pregnancy and lactation are limited. It should be used only if clearly needed and after a risk‑benefit assessment by the prescriber. Breastfeeding mothers should consult their healthcare provider before use.

To order Magaldrato Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Magaldrate combines magnesium and aluminum salts, offering a balanced antacid effect that can minimise the constipation associated with aluminum alone and the diarrhoea linked to magnesium alone. Compared with single‑component antacids, it often provides broader symptom control with a lower incidence of extreme gastrointestinal side effects.

Store Magaldrato Teva at ambient temperature, below 25 °C, in the original packaging. Keep the container tightly closed and protect it from moisture and direct sunlight to maintain product stability.

Magaldrato Teva is taken orally, usually with a glass of water. It may be taken with or without food, but to avoid interaction with other oral medications, separate dosing by at least two hours as advised by the prescriber.

Serious but rare risks include hypermagnesemia, especially in patients with renal impairment, and metabolic alkalosis from excessive acid neutralisation. Patients should be alert for symptoms such as muscle weakness, irregular heartbeat, or persistent vomiting and seek medical attention promptly.

Magaldrato Teva should be avoided in individuals with known hypersensitivity to magaldrate or its components, in patients with severe renal failure where magnesium accumulation is a concern, and in anyone advised against antacid therapy by their healthcare provider.